The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Assessing the real-world outcomes and safety of belzutifan in patients with VHL associated tumors
Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, discusses the rationale and objectives of assessing the real-world outcomes and safety of belzutifan in patients with VHL associated tumors. Belzutifan, a highly specific and well-tolerated HIF2α inhibitor, is approved for VHL-associated tumors in renal cell cancer, pancreatic neuroendocrine tumors, and CNS hemangioblastomas based on a Phase II (NCT03401788) clinical study involving 61 patients. However, real-world data on its use and efficacy are lacking. A study at CU Cancer Center aims to assess the outcomes and safety of belzutifan in this patient population to fill this gap and understand its effectiveness in a real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
